Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: A systematic review and meta-analysis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Ursini, Francesco ^a,c   Leporini, Christian ^a   Bene, Fabiola ^c   D'Angelo, Salvatore ^b   Mauro, Daniele ^c   Russo, Emilio ^a   De Sarro, Giovambattista ^a   Olivieri, Ignazio ^b   Pitzalis, Costantino ^c   Lewis, Myles ^c   Grembiale, Rosa Daniela ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SAN CARLO HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ANTAGONISTS AND INHIBITORS; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; META ANALYSIS; METABOLISM; PATHOLOGY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; ENDOTHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85023750434     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-05759-2     Document Type: Article

References (57)

1. Lindhardsen, J. et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 70, 929-934 (2011).
2. Innala, L. et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 13, R131, doi: 10.1186/ar3442 (2011).
3. van Breukelen-van der Stoep, D. F. et al. Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology (Oxford), doi: 10.1093/rheumatology/kew039 (2016).
4. Ursini, F. et al. Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis: an OGTT Study. Medicine (Baltimore) 95, e2552, doi: 10.1097/MD.0000000000002552 (2016).
5. Ursini, F. et al. Serum complement C3 strongly correlates with whole-body insulin sensitivity in rheumatoid arthritis. Clin Exp Rheumatol 35, 18-23 (2017).
6. Ursini, F., Grembiale, A., Naty, S. & Grembiale, R. D. Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. Clin Rheumatol 33, 1759-1764 (2014).
7. An, J. et al. Traditional Cardiovascular Risk Factor Management in Rheumatoid Arthritis Compared to Matched Non-Rheumatoid Arthritis in a US Managed Care Setting. Arthritis Care Res (Hoboken). doi: 10.1002/acr.22740 (2015).
8. Matsuzawa, Y., Kwon, T. G., Lennon, R. J., Lerman, L. O. & Lerman, A. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc 4, doi: 10.1161/JAHA.115.002270 (2015).
9. Di Minno, M. N. et al. Clinical assessment of endothelial function in patients with rheumatoid arthritis: A meta-analysis of literature studies. Eur J Intern Med 26, 835-842 (2015).
10. Ikdahl, E. et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 17, 279, doi: 10.1186/s13075-015-0795-y (2015).
11. Vita, J. A. Endothelial function. Circulation 124, e906-912, doi: 10.1161/CIRCULATIONAHA.111.078824 (2011).
12. Deanfield, J. E., Halcox, J. P. & Rabelink, T. J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115, 1285-1295 (2007).
13. Plutzky, J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2, 327-335 (2000).
14. Flammer, A. J. et al. The assessment of endothelial function: from research into clinical practice. Circulation 126, 753-767 (2012).
15. Ross, R. Atherosclerosis-an inflammatory disease. N Engl J Med 340, 115-126 (1999).
16. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
17. Roubille, C. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74, 480-489 (2015).
18. Barnabe, C., Martin, B. J. & Ghali, W. A. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63, 522-529 (2011).
19. Ursini, F. et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 94, e888, doi: 10.1097/MD.0000000000000888 (2015).
20. Ursini, F., Mauro, D., Naty, S., Gagliardi, D. & Grembiale, R. D. Improvement in insulin resistance after short-term treatment with abatacept: case report and short review. Clin Rheumatol 31, 1401-1402 (2012).
21. Ursini, F. TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade. Reumatismo 61(4), 254-259 (2009).
22. Tam, L. S., Kitas, G. D. & Gonzalez-Gay, M. A. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 53, 1108-1119 (2014).
23. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-2012 (2000).
24. Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14, 135, doi: 10.1186/1471-2288-14-135 (2014).
25. Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5, 13, doi:1471-2288-5-13 (2005).
26. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557-560 (2003).
27. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997).
28. Duval, S. & Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455-463 (2000).
29. Bilsborough, W. et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26, 1125-1131 (2006).
30. Bosello, S. et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27, 833-839 (2008).
31. Capria, A. et al. Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 23, 255-262 (2010).
32. Capria, A. et al. Endothelial dysfunction in rheumatoid arthritis is improved by anti-tumor necrosis factorα treatment. European Journal of Inflammation 2, 113-118 (2004).
33. Foster, W., Carruthers, D., Lip, G. Y. H. & Blann, A. D. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: Effect of treatment. Journal of Rheumatology 37, 711-716 (2010).
34. Gonzalez-Juanatey, C. et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24, 309-312 (2006).
35. Gonzalez-Juanatey, C. et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm 2012, 674265, doi: 10.1155/2012/674265 (2012).
36. Hürlimann, D. et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
37. Irace, C. et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177, 113-118 (2004).
38. Kerekes, G. et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 13, 147-152 (2011).
39. Komai, N., Morita, Y., Sakuta, T., Kuwabara, A. & Kashihara, N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Modern Rheumatology 17, 385-390 (2007).
40. Maki-Petaja, K. M. et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 126, 2473-2480 (2012).
41. Park, Y. J. et al. Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis. Arthritis and Rheumatology 66, 1450-1460 (2014).
42. Sandoo, A., Kitas, G. D., Carroll, D. & Veldhuijzen van Zanten, J. J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther 14, R117, doi: 10.1186/ar3847 (2012).
43. Sandoo, A., Van Zanten, J. J. C. S. V., Toms, T. E., Carroll, D. & Kitas, G. D. Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: A Pilot Study. BMC Musculoskeletal Disorders 13, doi: 10.1186/1471-2474-13-127 (2012).
44. Spinelli, F. R. et al. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators of Inflammation 2013, doi: 10.1155/2013/537539 (2013).
45. Hjeltnes, G. et al. Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-alpha inhibitor in rheumatoid arthritis patients. Scand J Rheumatol 41, 240-242 (2012).
46. Hjeltnes, G. et al. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor. Clin Exp Rheumatol 31, 415-421 (2013).
47. Sidiropoulos, P. I. et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 38, 6-10 (2009).
48. Tikiz, H., Arslan, O., Pirildar, T., Tikiz, C. & Bayindir, P. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. Anadolu Kardiyol Derg 10, 98-103 (2010).
49. Zhang, J. et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis, doi:annrheumdis-2015-207870 (2016).
50. Mathieu, S., Couderc, M., Pereira, B. & Soubrier, M. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 43, e1-2, doi: 10.1016/j.semarthrit.2013.05.005 (2013).
51. Hjeltnes, G. et al. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-alpha inhibitors. J Rheumatol 39, 1341-1347 (2012).
52. Hjeltnes, G. et al. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clinical and Experimental Rheumatology 31, 415-421 (2013).
53. Sandoo, A., van Zanten, J. J., Toms, T. E., Carroll, D. & Kitas, G. D. Anti-TNFalpha therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord 13, 127, doi: 10.1186/1471-2474-13-127 (2012).
54. Sandoo, A. et al. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clin Biochem 45, 1399-1403 (2012).
55. Foster, W., Carruthers, D., Lip, G. Y. & Blann, A. D. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J Rheumatol 37, 711-716 (2010).
56. Turiel, M. et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 28, e53-64, doi: 10.1111/j.1755-5922.2009.00119.x (2010).
57. Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59, 1821-1824 (2008).